Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Stock Transactions
SEC Form 4 Filing
Chandler Robinson, CEO of Monopar Therapeutics, reports acquisition and disposal of common stock and derivative securities related to vesting of restricted stock units and stock options.
Summary
- On March 4, 2025, Chandler Robinson, CEO of Monopar Therapeutics, reported transactions involving the company's stock.
- These transactions included the acquisition of 6,002 shares of common stock upon the vesting and settlement of restricted stock units.
- Robinson also disposed of 1,759 shares to cover withholding taxes related to the vesting of these units at a price of $31.7 per share.
- Following these transactions, Robinson directly owns 63,091 shares of common stock.
- Robinson also indirectly owns 855,589 shares through Tactic Pharma LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
- Additionally, Robinson acquired 85,759 stock options with an exercise price of $31.7, vesting in installments until June 2029 and expiring in 2035.
- He also holds 104,777 restricted stock units, vesting in installments.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with SEC regulations.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal as it relates to previously awarded compensation.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of earliest transaction (acquisition/disposal of shares and derivative securities). |
| 03/04/2025 | Vesting date of 6,002 restricted stock units. |
| 03/04/2035 | Expiration date of stock options. |
| 03/07/2025 | Date of signature for the report. |
| June 30, 2025 | Next vesting date for remaining options and restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.